Cargando…

Challenges in Transition From Childhood to Adulthood Care in Rare Metabolic Diseases: Results From the First Multi-Center European Survey

Inherited Metabolic Diseases (IMDs) are rare diseases caused by genetic defects in biochemical pathways. Earlier diagnosis and advances in treatment have improved the life expectancy of IMD patients over the last decades, with the majority of patients now surviving beyond the age of 20. This has cre...

Descripción completa

Detalles Bibliográficos
Autores principales: Stepien, Karolina M., Kieć-Wilk, Beata, Lampe, Christina, Tangeraas, Trine, Cefalo, Graziella, Belmatoug, Nadia, Francisco, Rita, del Toro, Mireia, Wagner, Leona, Lauridsen, Anne-Grethe, Sestini, Sylvia, Weinhold, Nathalie, Hahn, Andreas, Montanari, Chiara, Rovelli, Valentina, Bellettato, Cinzia M., Paneghetti, Laura, van Lingen, Corine, Scarpa, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962750/
https://www.ncbi.nlm.nih.gov/pubmed/33738294
http://dx.doi.org/10.3389/fmed.2021.652358
_version_ 1783665517509214208
author Stepien, Karolina M.
Kieć-Wilk, Beata
Lampe, Christina
Tangeraas, Trine
Cefalo, Graziella
Belmatoug, Nadia
Francisco, Rita
del Toro, Mireia
Wagner, Leona
Lauridsen, Anne-Grethe
Sestini, Sylvia
Weinhold, Nathalie
Hahn, Andreas
Montanari, Chiara
Rovelli, Valentina
Bellettato, Cinzia M.
Paneghetti, Laura
van Lingen, Corine
Scarpa, Maurizio
author_facet Stepien, Karolina M.
Kieć-Wilk, Beata
Lampe, Christina
Tangeraas, Trine
Cefalo, Graziella
Belmatoug, Nadia
Francisco, Rita
del Toro, Mireia
Wagner, Leona
Lauridsen, Anne-Grethe
Sestini, Sylvia
Weinhold, Nathalie
Hahn, Andreas
Montanari, Chiara
Rovelli, Valentina
Bellettato, Cinzia M.
Paneghetti, Laura
van Lingen, Corine
Scarpa, Maurizio
author_sort Stepien, Karolina M.
collection PubMed
description Inherited Metabolic Diseases (IMDs) are rare diseases caused by genetic defects in biochemical pathways. Earlier diagnosis and advances in treatment have improved the life expectancy of IMD patients over the last decades, with the majority of patients now surviving beyond the age of 20. This has created a new challenge: as they grow up, the care of IMD patients' needs to be transferred from metabolic pediatricians to metabolic physicians specialized in treating adults, through a process called “transition.” The purpose of this study was to assess how this transition is managed in Europe: a survey was sent to all 77 centers of the European Reference Network for Hereditary Metabolic Disorders (MetabERN) to collect information and to identify unmet needs regarding the transition process. Data was collected from 63/77 (81%) healthcare providers (HCPs) from 20 EU countries. Responders were mostly metabolic pediatricians; of these, only ~40% have received appropriate training in health issues of adolescent metabolic patients. In most centers (~67%) there is no designated transition coordinator. About 50% of centers provide a written individualized transition protocol, which is standardized in just ~20% of cases. In 77% of centers, pediatricians share a medical summary, transition letter and emergency plan with the adult team and the patient. According to our responders, 11% of patients remain under pediatric care throughout their life. The main challenges identified by HCPs in managing transition are lack of time and shortage of adult metabolic physician positions, while the implementations that are most required for a successful transition include: medical staff dedicated to transition, a transition coordinator, and specific metabolic training for adult physicians. Our study shows that the transition process of IMD patients in Europe is far from standardized and in most cases is inadequate or non-existent. A transition coordinator to facilitate collaboration between the pediatric and adult healthcare teams should be central to any transition program. Standardized operating procedures, together with adequate financial resources and specific training for adult physicians focused on IMDs are the key aspects that must be improved in the rare metabolic field to establish successful transition processes in Europe.
format Online
Article
Text
id pubmed-7962750
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79627502021-03-17 Challenges in Transition From Childhood to Adulthood Care in Rare Metabolic Diseases: Results From the First Multi-Center European Survey Stepien, Karolina M. Kieć-Wilk, Beata Lampe, Christina Tangeraas, Trine Cefalo, Graziella Belmatoug, Nadia Francisco, Rita del Toro, Mireia Wagner, Leona Lauridsen, Anne-Grethe Sestini, Sylvia Weinhold, Nathalie Hahn, Andreas Montanari, Chiara Rovelli, Valentina Bellettato, Cinzia M. Paneghetti, Laura van Lingen, Corine Scarpa, Maurizio Front Med (Lausanne) Medicine Inherited Metabolic Diseases (IMDs) are rare diseases caused by genetic defects in biochemical pathways. Earlier diagnosis and advances in treatment have improved the life expectancy of IMD patients over the last decades, with the majority of patients now surviving beyond the age of 20. This has created a new challenge: as they grow up, the care of IMD patients' needs to be transferred from metabolic pediatricians to metabolic physicians specialized in treating adults, through a process called “transition.” The purpose of this study was to assess how this transition is managed in Europe: a survey was sent to all 77 centers of the European Reference Network for Hereditary Metabolic Disorders (MetabERN) to collect information and to identify unmet needs regarding the transition process. Data was collected from 63/77 (81%) healthcare providers (HCPs) from 20 EU countries. Responders were mostly metabolic pediatricians; of these, only ~40% have received appropriate training in health issues of adolescent metabolic patients. In most centers (~67%) there is no designated transition coordinator. About 50% of centers provide a written individualized transition protocol, which is standardized in just ~20% of cases. In 77% of centers, pediatricians share a medical summary, transition letter and emergency plan with the adult team and the patient. According to our responders, 11% of patients remain under pediatric care throughout their life. The main challenges identified by HCPs in managing transition are lack of time and shortage of adult metabolic physician positions, while the implementations that are most required for a successful transition include: medical staff dedicated to transition, a transition coordinator, and specific metabolic training for adult physicians. Our study shows that the transition process of IMD patients in Europe is far from standardized and in most cases is inadequate or non-existent. A transition coordinator to facilitate collaboration between the pediatric and adult healthcare teams should be central to any transition program. Standardized operating procedures, together with adequate financial resources and specific training for adult physicians focused on IMDs are the key aspects that must be improved in the rare metabolic field to establish successful transition processes in Europe. Frontiers Media S.A. 2021-02-25 /pmc/articles/PMC7962750/ /pubmed/33738294 http://dx.doi.org/10.3389/fmed.2021.652358 Text en Copyright © 2021 Stepien, Kieć-Wilk, Lampe, Tangeraas, Cefalo, Belmatoug, Francisco, del Toro, Wagner, Lauridsen, Sestini, Weinhold, Hahn, Montanari, Rovelli, Bellettato, Paneghetti, van Lingen and Scarpa. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Stepien, Karolina M.
Kieć-Wilk, Beata
Lampe, Christina
Tangeraas, Trine
Cefalo, Graziella
Belmatoug, Nadia
Francisco, Rita
del Toro, Mireia
Wagner, Leona
Lauridsen, Anne-Grethe
Sestini, Sylvia
Weinhold, Nathalie
Hahn, Andreas
Montanari, Chiara
Rovelli, Valentina
Bellettato, Cinzia M.
Paneghetti, Laura
van Lingen, Corine
Scarpa, Maurizio
Challenges in Transition From Childhood to Adulthood Care in Rare Metabolic Diseases: Results From the First Multi-Center European Survey
title Challenges in Transition From Childhood to Adulthood Care in Rare Metabolic Diseases: Results From the First Multi-Center European Survey
title_full Challenges in Transition From Childhood to Adulthood Care in Rare Metabolic Diseases: Results From the First Multi-Center European Survey
title_fullStr Challenges in Transition From Childhood to Adulthood Care in Rare Metabolic Diseases: Results From the First Multi-Center European Survey
title_full_unstemmed Challenges in Transition From Childhood to Adulthood Care in Rare Metabolic Diseases: Results From the First Multi-Center European Survey
title_short Challenges in Transition From Childhood to Adulthood Care in Rare Metabolic Diseases: Results From the First Multi-Center European Survey
title_sort challenges in transition from childhood to adulthood care in rare metabolic diseases: results from the first multi-center european survey
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962750/
https://www.ncbi.nlm.nih.gov/pubmed/33738294
http://dx.doi.org/10.3389/fmed.2021.652358
work_keys_str_mv AT stepienkarolinam challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT kiecwilkbeata challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT lampechristina challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT tangeraastrine challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT cefalograziella challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT belmatougnadia challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT franciscorita challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT deltoromireia challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT wagnerleona challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT lauridsenannegrethe challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT sestinisylvia challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT weinholdnathalie challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT hahnandreas challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT montanarichiara challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT rovellivalentina challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT bellettatocinziam challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT paneghettilaura challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT vanlingencorine challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey
AT scarpamaurizio challengesintransitionfromchildhoodtoadulthoodcareinraremetabolicdiseasesresultsfromthefirstmulticentereuropeansurvey